Key Insights:
- The American Gastroenterological Association (AGA) has released new guidelines that emphasize the use of biomarkers in managing Crohn’s disease, both in active cases and during remission. This reflects a significant shift towards a more non-invasive approach in monitoring this condition.
- The guidelines advocate for the use of blood and stool-based biomarkers, such as C-reactive protein (CRP) and fecal calprotectin (FCP), as less invasive, more cost-effective alternatives to frequent colonoscopies. These biomarkers help determine the inflammatory status of the disease and guide treatment adjustments.
- The guidelines offer specific recommendations on the frequency and context for using these biomarkers. For instance, in symptomatic remission, CRP and FCP should be checked every 6 to 12 months to rule out active inflammation, potentially avoiding unnecessary endoscopy.